89BIO (ETNB)
(Real Time Quote from BATS)
$8.04 USD
-0.31 (-3.71%)
Updated Jul 22, 2024 11:34 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ETNB 8.04 -0.31(-3.71%)
Will ETNB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ETNB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ETNB
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy
Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success
ETNB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
89BIO (ETNB) Just Overtook the 200-Day Moving Average
Other News for ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Buy Rating Affirmed on 89bio Due to Pegozafermin’s Promising Trial Results and Strategic Position in NASH Treatment Landscape
Buy Rating Affirmed for 89bio Following Promising Pegozafermin Trial Results
Madrigal, 89bio, Akero slip after Eli Lilly MASH data released